BioMarin Pharmaceutical Inc. (BMRN) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-26
How it makes money
It earns revenue by selling specialized genetic and enzyme therapies to patients with rare diseases, with VOXZOGO driving recent growth.
BioMarin generates its revenue through commercializing a portfolio of specialized therapies targeted at genetically defined rare conditions. Its top revenue driver is VOXZOGO, which generated $926.9 million in 2025 net product revenues for the treatment of achondroplasia. Alongside VOXZOGO, it sells a stable of enzyme therapies, including VIMIZIM, NAGLAZYME, PALYNZIQ, ALDURAZYME, and BRINEURA, which cater to specific rare metabolic and neurological disorders.
Total revenues reached $3,221.3 million in 2025, up from $2,853.9 million in 2024. Profitability is directly influenced by the successful commercial expansion of these rare disease treatments into larger patient populations and the continuous management of manufacturing and operating expenses.
What protects it: the moat
It relies on its proprietary drug discovery approach, regulatory exclusivity, and complex biologic manufacturing expertise to protect its market position.
BioMarin operates in the specialized rare disease biotechnology sector, where developing category-defining medicines creates high barriers to entry for potential competitors. Management asserts that its distinctive approach to drug discovery, combined with established clinical and preclinical pipelines, allows it to deliver complex therapies for genetically defined conditions.
However, the company faces constant competition to acquire or license promising external assets from academic research institutions and other biotechnology firms. Because competitors frequently target similar rare diseases and vie for the same collaboration opportunities, the company must continually innovate and successfully manage its acquired portfolios to maintain its competitive moat.
What growth costs
It reinvests heavily through research and development, selling, general and administrative expenses, and substantial acquisitions to expand its pipeline.
To sustain and grow its earnings, the company commits substantial capital to research and development, which totaled $921.9 million in 2025, compared to $747.2 million in 2024. Selling, general and administrative expenses also represent a major reinvestment category, reaching $1,153.0 million in 2025 up from $1,009.0 million in the prior year. Cost of sales stood at $717.4 million in 2025.
Beyond internal R&D, it aggressively pursues external growth through corporate acquisitions and asset purchases. It completed the acquisition of Inozyme Pharma, Inc. in July 2025 to secure a late-stage enzyme replacement therapy, and it entered a definitive agreement in December 2025 to acquire Amicus Therapeutics, Inc. for approximately $4.8 billion, financed partially through $3.7 billion of debt commitments.
What could damage it
Inability to successfully execute its growth strategy or integrate large acquisitions could materially and adversely affect its financial condition.
The company is actively expanding its operations by targeting larger patient populations and executing major corporate transactions, such as the pending acquisition of Amicus for approximately $4.8 billion using significant debt financing. If management fails to effectively manage this rapid expansion or if the anticipated benefits from these strategic initiatives and acquired pipelines fail to materialize, the resulting integration costs and debt service obligations could severely damage operating results.
Furthermore, the biopharmaceutical development process is inherently uncertain; if clinical programs fail to meet regulatory standards or commercial expectations—as demonstrated by the voluntary withdrawal of ROCTAVIAN and the recording of approximately $240.0 million in restructuring charges—future earnings and cash flows would experience permanent impairment.
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.